Sunday, August 16, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
InjectablesHugel Posts Record H1 on Toxin Surge—Overseas Growth AcceleratestodayMarketHugel Posts Record H1 Revenue on Overseas Toxin Surge3 days agoDevices & TechApyx: GLP-1 Boom Is Fueling Renuvion DemandtodayMarketMedytox Q2 Sales Up 11%, Operating Profit Down 25%3 days agoInjectablesGalderma Wins EU Nod for Restylane ShaypeyesterdayBusiness & M&AEstablishment Labs Raises 2026 Revenue Guidance2 days agoDevices & TechMerz Ultherapy PRIME Clears FDA for Knee Skin LaxityyesterdayBusiness & M&ABeauty Health Q2 Earnings: Device Demand Steady2 days agoInjectablesHugel Debuts Thechaum Signature with Reduced CrosslinkeryesterdayDevices & TechAlma Launches TitaniumLift™ Multi-Depth RF Protocol2 days agoInjectablesGLP-1 Boom Exposed Filler Limitations—Here's WhyyesterdayInjectablesGalderma Chief: Start GLP-1 Patients on Skin Care First2 days ago
Markets & Filings

Consent Decree

A court-approved settlement where a company agrees to conditions to resolve a government enforcement case.

Also known as: Consent Order, Settlement Agreement

What it is
A consent decree is a binding, court-approved agreement resolving a government enforcement action without admission of liability. The company agrees to remedies like divestitures, conduct limits, or compliance obligations. It ends the immediate legal fight.
What it does
A consent decree removes overhang uncertainty, often relieving a stock, but the required remedies can constrain future business. Investors weigh the relief against the operational cost of the terms. It can clear a merger to close with divestitures.
The evidence
Merger approvals conditioned on divestiture consent decrees have let deals close and lifted acquirers' shares on removed uncertainty.
Best for
Companies under enforcement or with pending merger reviews.
Pairs well with
antitrust-action, 8-k, event-driven
Use cautiously with
The remedies can be onerous; reading a settlement as pure good news ignores the ongoing compliance and divestiture drag.
Cautions
Terms may cap growth for years, so relief rallies can fade as constraints bite.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

More markets & filings

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Inside MedSpa Pro.

Go Pro · $20/mo
Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo →